These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Todd PA; Goa KL Drugs; 1992 Mar; 43(3):346-81. PubMed ID: 1374319 [TBL] [Abstract][Full Text] [Related]
44. The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension. Osswald H; Mühlbauer B J Hypertens Suppl; 1995 Aug; 13(2):S21-8. PubMed ID: 8576784 [TBL] [Abstract][Full Text] [Related]
51. Lercanidipine/enalapril combination in the management of obesity-related hypertension. Grassi G Integr Blood Press Control; 2016; 9():69-77. PubMed ID: 27175094 [TBL] [Abstract][Full Text] [Related]
52. [Dihydropyridines from the first to the fourth generation: better effects and safety]. Aouam K; Berdeaux A Therapie; 2003; 58(4):333-9. PubMed ID: 14679672 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Rump LC Arzneimittelforschung; 2010; 60(3):124-30. PubMed ID: 20422943 [TBL] [Abstract][Full Text] [Related]
54. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril. Chatzikyrkou C; Haller H; Menne J Expert Opin Pharmacother; 2009 Aug; 10(11):1833-40. PubMed ID: 19527194 [TBL] [Abstract][Full Text] [Related]
55. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. Egan CG; Pontremoli R J Nephrol; 2011; 24(4):428-37. PubMed ID: 21279953 [TBL] [Abstract][Full Text] [Related]
57. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Burnier M; Pruijm M; Wuerzner G Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074 [TBL] [Abstract][Full Text] [Related] [Previous] [New Search]